Send a Tweet
Most Popular Choices
Share on Facebook 9 Share on Twitter Printer Friendly Page More Sharing
Exclusive to OpEdNews:
Life Arts   

Statin Anti-Cholesterol Drugs Revisited

By       (Page 2 of 7 pages) Become a premium member to see this article and all articles as one long page.     (# of views)   No comments
Author 30652
Follow Me on Twitter     Message Jeffrey Dach
Become a Fan
  (12 fans)
Perhaps the best single review of primary prevention of heart disease with statin drugs comes from Dr Ray in the 2010 Archives of Internal Medicine. (9,10)  Dr. Ray reviewed 11 randomized Statin Drug trials with 65,000 participants finding NO ALL-Cause Mortality Benefit from statin drug treatment to reduce cholesterol values in primary prevention of heart disease (people without known heart disease).(9,10)

Dr Stephen Sinatra- Restrict Statin Drugs to Men with Known Heart Disease (11)

Now we can summarize the above information.  In Women and the Elderly, Statin drugs offer no mortality benefit for primary or secondary prevention of heart disease.

In addition, Statin drugs offer no mortality benefit for men in primary prevention of heart disease (men with no known heart disease). 

This leaves us with the remaining group in which statin drugs HAVE BEEN SHOWN to provide a mortality benefit.  This group is males with known heart disease, also called secondary prevention.

And now, we can understand the rationale for Dr Stephen Sinatra's position on statin drugs announced in his newsletter.(11)  Dr. Sinatra says that statin drugs should be prescribed only to middle aged males with known heart disease.  For other groups, Dr Sinatra considers statin drugs unnecessary and potentially harmful. (11)

Secondary Prevention of Heart Disease in Males

Considering the media and marketing hype over statin drugs, one would think there must be something to it, so let's take a look at the statin drug studies in the best case scenario, middle aged men with known heart disease.  This is the group with proven mortality benefit and these studies were submitted for FDA approval for this class of drugs. Let's take a closer look at the data from two of the most representative secondary prevention studies with statin drugs, the 4S (12,13) and the LIPID Studies (14).

4S Trial with Simvastatin in Scandinavia (12,13) - 0.6% per year

Here is a quick recap of the 4S-Trial data.

The 4S trial was done on 4444 patients who had known heart disease, randomized to simvastatin or placebo, and followed for 5.5 years.  At the end of the follow up, they reported 182 deaths in the statin drug group (8.2 %) and 256 deaths in the placebo group (11.5% ).  This provided  an absolute mortality benefit of 3.3% over 5.5 years, or 0.6% per year. (12,13)  The 6-year probabilities of survival for placebo was 88.5 % and for simvastatin was 91.8%, a difference of 3.3%.

LIPID Pravastatin  Study (14) - 0.5% per year

Here is a quick recap of the LIPID Trial data. 

9,000 patients with unstable angina and history of myocardial infarction were randomized to either placebo or Pravastatin and followed for 6.1 years.(14)

The statin group had 11% mortality and the placebo group had 14.1 % mortality over 6.1 years.  This is a 3.1% mortality benefit over 6.1 years or 0.5% per year.  After 6 years probability of survival in the placebo group is 85.9% and in the Statin drug group is 89%, a difference of 3.1 %.   (14)

Absolute Mortality Benefit of 0.5% per year in Secondary Prevention

So, as you can see from the above, the absolute mortality benefit in the best case scenario, in secondary prevention trials, is only 0.5% - 0.6% per year.  This benefit is underwhelming, and actually quite shocking that it is such a minimal benefit when the drug company marketing would suggest much larger benefits.

Next Page  1  |  2  |  3  |  4  |  5  |  6  |  7


Rate It | View Ratings

Jeffrey Dach Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Jeffrey Dach MD is a physician and author of three books, Natural Medicine 101, and Bioidentical Hormones 101, and Heart Book all available on Amazon, or as a free e-book on his web sites. Dr. Dach is founder and chief medical officer of (more...)

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
   (Opens new browser window)

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Failed Hatchet Job on Larry King, Suzanne Somers, Knockout

Bioidentical Hormones on Oprah, Are They Safe?

Why Natural Thyroid is Better than Synthetic

Wheatgrass, Natural Medicine in the Kitchen

Fish Oil Increases Risk for Prostate Cancer, New Study?

Spontaneous Remission Cancer Breakthrough